REBECCA INGERSOLL: Open Payments
NPI 1174906697 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$619 in 36 payments from 13 companies in 2025. Trend: 2023 $1,085 · 2024 $856 · 2025 $619
Food & beverage: $619
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $150 |
| Amgen Inc. | 5 | $109 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| Xeris Pharmaceuticals, Inc. | 2 | $51 |
| Novo Nordisk Inc | 2 | $40 |
| Abbott Laboratories | 2 | $39 |
| Lilly USA, LLC | 1 | $28 |
| Exact Sciences Corporation | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: Auvelity, VRAYLAR, OTEZLA, UBRELVY, GVOKE HYPOPEN, Ozempic, FREESTYLE LIBRE 3, MOUNJARO.
Industry payments across OH — which companies pay providers there.
